PrefHer: finally addressing the preferences of her, too
Menée sur 248 patientes atteintes d'un adénocarcinome invasif du sein HER2+, cette étude évalue leurs préférences en matière de modalité d'administration du trastuzumab, par voie sous-cutanée ou intraveineuse
The development of trastuzumab is an example of the successful implementation of targeted therapy. Despite the advent of other agents that target HER2, such as lapatinib, pertuzumab, or trastuzumab emtansine, trastuzumab remains the main treatment for HER2-positive breast cancer in the metastatic, adjuvant, and neoadjuvant settings. Irrespective of the stage at presentation, anti-HER2 therapy has changed the natural history of the disease. Paradoxically, as a result of this success, ...